Sign In
Buy NBSE
$0.378
+0 (+0%)
At Close: Aug 09, 2024
Global Age-Related Macular Degeneration Market and Competitive Landscape 2020 - ResearchAndMarkets.com
12:00am, Tuesday, 12'th May 2020
The
Merger Arb Trade Review: AbbVie And Allergan
06:33pm, Monday, 11'th May 2020
In August 2019 I suggested a partially hedged trade of selling AbbVie and using the proceeds plus extra cash to buy Allergan for a 17% return on cash. Now that
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer
12:00am, Thursday, 07'th May 2020
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer
IVERIC bio : Reports First Quarter 2020 Operational Highlights and Financial Results | MarketScreener
11:27am, Wednesday, 06'th May 2020NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08:05pm, Thursday, 30'th Apr 2020
NeuBase Therapeutics, Inc. (NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the
NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
01:44pm, Tuesday, 28'th Apr 2020
NeuBase Therapeutics, Inc. (NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the
NeuBase Therapeutics Announces Proposed Public Offering of Common Stock
08:01pm, Monday, 27'th Apr 2020
PITTSBURGH, April 27, 2020 -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare.
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
12:03pm, Wednesday, 15'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Accelero
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 13.) * Chembio Diagnostics Inc (NASDAQ: CEMI)
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 13.)
Chembio...
NeuBase Therapeutics (NBSE) Gets a Buy Rating from H.C. Wainwright
11:16am, Wednesday, 01'st Apr 2020
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) today and set a
NeuBase Therapeutics (NBSE) Gets a Buy Rating from Oppenheimer
03:00pm, Tuesday, 31'st Mar 2020
Oppenheimer analyst Hartaj Singh maintained a Buy rating on NeuBase Therapeutics (NBSE – Research Report) today. The company’s shares closed
NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform
11:01am, Tuesday, 31'st Mar 2020
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (“ASO”) therapies to address genetic d
Head-To-Head Review: OHR Pharmaceutical (NASDAQ:OHRP) versus Catalent (NASDAQ:CTLT)
05:24am, Tuesday, 31'st Mar 2020
OHR Pharmaceutical (NASDAQ:OHRP) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst re
NeuBase Therapeutics (NBSE) Gets a Buy Rating from Chardan Capital
12:11pm, Friday, 27'th Mar 2020
Chardan Capital analyst Keay Nakae reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) today and set a
